Skip to content

Dyskeratosis Congenita Autosomal Dominant 6 C4225284

Published: July 22, 2026Updated: August 20, 2026

This autosomal dominant telomere disorder causes mucocutaneous abnormalities and systemic involvement. It carries elevated risk for bone marrow problems and cancer. Treatment requires regular monitoring and supportive management.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Hematopoietic stem cell transplantation

Transplantation using healthy donor stem cells to restore bone marrow function, offering potential cure for the hematologic manifestations of autosomal dominant dyskeratosis congenita type 6.

surgical
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Eltrombopag for thrombocytopenia

Thrombopoietin receptor agonist to stimulate platelet production in patients with hypoproliferative thrombocytopenia, providing transfusion independence while awaiting definitive therapy.

medication

Additional treatment options

Telomere length surveillance

Periodic measurement of peripheral blood leukocyte telomere length to assess disease progression and treatment response, guiding clinical management decisions.

monitoring

Iron chelation therapy

Management of secondary hemochromatosis from chronic transfusions using iron chelators to prevent cardiac and hepatic iron accumulation.

procedure

Genetic counseling and family support

Comprehensive genetic counseling for patients and family members regarding inheritance patterns, reproductive options, and family screening given autosomal dominant transmission.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dyskeratosis Congenita Autosomal Dominant 6 C4225284?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dyskeratosis Congenita Autosomal Dominant 6 C4225284. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy